Press Releases InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market November 18, 2022 Read More » InMed Provides Update on Management Changes November 17, 2022 Read More » InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada (“NSERC”) Alliance Grant Funding November 16, 2022 Read More » InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update November 11, 2022 Read More » Registration Now Open For Tribe Public’s Webinar Event “Exploring the Neuroprotective Qualities of Rare Cannabinoids” Featuring InMed’s Management Team On November 17, 2022 November 10, 2022 Read More » InMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness Week October 26, 2022 Read More » InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update September 23, 2022 Read More » InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market September 13, 2022 Read More » InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market September 9, 2022 Read More » InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business September 8, 2022 Read More » InMed Announces Share Consolidation to Meet Nasdaq Listing Criteria August 23, 2022 Read More » InMed Announces Changes to its Board of Directors August 9, 2022 Read More » InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa July 25, 2022 Read More » InMed Announces Appointment of Chief Operating Officer July 18, 2022 Read More » InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance July 12, 2022 Read More » InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions June 14, 2022 Read More » InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector June 9, 2022 Read More » InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules June 6, 2022 Read More » InMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules June 2, 2022 Read More » InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update May 13, 2022 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Next » Management Learn More Board of Directors Learn More Scientific Advisory Board Learn More Investor Alerts Sign up to receive news releases from InMed Pharmaceuticals. SIGN UP
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market November 18, 2022 Read More »
InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada (“NSERC”) Alliance Grant Funding November 16, 2022 Read More »
InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update November 11, 2022 Read More »
Registration Now Open For Tribe Public’s Webinar Event “Exploring the Neuroprotective Qualities of Rare Cannabinoids” Featuring InMed’s Management Team On November 17, 2022 November 10, 2022 Read More »
InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update September 23, 2022 Read More »
InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market September 13, 2022 Read More »
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market September 9, 2022 Read More »
InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business September 8, 2022 Read More »
InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa July 25, 2022 Read More »
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance July 12, 2022 Read More »
InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions June 14, 2022 Read More »
InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector June 9, 2022 Read More »
InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules June 6, 2022 Read More »
InMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules June 2, 2022 Read More »
InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update May 13, 2022 Read More »